These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37019886)

  • 1. The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis.
    Raballo A; Poletti M; Preti A
    Transl Psychiatry; 2023 Apr; 13(1):112. PubMed ID: 37019886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk: A Systematic Review and Meta-Analysis.
    Raballo A; Poletti M; Preti A
    JAMA Psychiatry; 2024 Jul; 81(7):727-730. PubMed ID: 38506802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analyzing the prevalence and prognostic effect of antipsychotic exposure in clinical high-risk (CHR): when things are not what they seem.
    Raballo A; Poletti M; Preti A
    Psychol Med; 2020 Dec; 50(16):2673-2681. PubMed ID: 33198845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative Prognostic Effect of Baseline Antipsychotic Exposure in Clinical High Risk for Psychosis (CHR-P): Is Pre-Test Risk Enrichment the Hidden Culprit?
    Raballo A; Poletti M; Preti A
    Int J Neuropsychopharmacol; 2021 Sep; 24(9):710-720. PubMed ID: 34036323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis.
    Raballo A; Poletti M; Preti A
    Psychol Med; 2023 Aug; ():1-7. PubMed ID: 37609894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: Findings from the Parma At-Risk Mental States (PARMS) program.
    Pelizza L; Leuci E; Quattrone E; Azzali S; Paulillo G; Pupo S; Poletti M; Raballo A; Pellegrini P; Menchetti M
    Early Interv Psychiatry; 2024 Feb; 18(2):71-81. PubMed ID: 37194411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis.
    Raballo A; Poletti M; Preti A
    Psychol Med; 2023 Jul; 53(10):4550-4560. PubMed ID: 35655405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis.
    Salazar de Pablo G; Soardo L; Cabras A; Pereira J; Kaur S; Besana F; Arienti V; Coronelli F; Shin JI; Solmi M; Petros N; Carvalho AF; McGuire P; Fusar-Poli P
    Epidemiol Psychiatr Sci; 2022 Jan; 31():e9. PubMed ID: 35042573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study.
    Zeng J; Raballo A; Gan R; Wu G; Wei Y; Xu L; Tang X; Hu Y; Tang Y; Chen T; Li C; Wang J; Zhang T
    J Clin Psychiatry; 2022 Mar; 83(3):. PubMed ID: 35324095
    [No Abstract]   [Full Text] [Related]  

  • 10. Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period.
    Pelizza L; Di Lisi A; Leuci E; Quattrone E; Azzali S; Pupo S; Paulillo G; Pellegrini P; Menchetti M
    Schizophr Bull; 2024 Mar; ():. PubMed ID: 38551332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis).
    Zhang T; Xu L; Tang X; Wei Y; Hu Q; Hu Y; Cui H; Tang Y; Hui L; Li C; Cao L; Lu Z; Wang J
    Aust N Z J Psychiatry; 2020 Jul; 54(7):696-706. PubMed ID: 32436725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When to initiate antipsychotic treatment for psychotic symptoms: At the premorbid phase or first episode of psychosis?
    Zhang T; Xu L; Wei Y; Tang X; Hu Y; Cui H; Tang Y; Xie B; Li C; Wang J
    Aust N Z J Psychiatry; 2021 Mar; 55(3):314-323. PubMed ID: 33143440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis.
    Oliver D; Arribas M; Radua J; Salazar de Pablo G; De Micheli A; Spada G; Mensi MM; Kotlicka-Antczak M; Borgatti R; Solmi M; Shin JI; Woods SW; Addington J; McGuire P; Fusar-Poli P
    Mol Psychiatry; 2022 Sep; 27(9):3670-3678. PubMed ID: 35665763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic and functional remission of subjects at clinical high risk for psychosis: a 2-year naturalistic observational study.
    Lee TY; Kim SN; Correll CU; Byun MS; Kim E; Jang JH; Kang DH; Yun JY; Kwon JS
    Schizophr Res; 2014 Jul; 156(2-3):266-71. PubMed ID: 24815568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.
    Zhang T; Wang J; Xu L; Wei Y; Tang X; Hu Y; Cui H; Tang Y; Li C; Ling Z; Wang J
    Eur Arch Psychiatry Clin Neurosci; 2022 Jun; 272(4):591-602. PubMed ID: 34536114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Changes in Cortical Surface Area Associated With Transition to Psychosis in Adolescents at Clinical High Risk for the Disease.
    Fortea A; van Eijndhoven P; Ilzarbe D; Batalla A; Calvet-Mirabent A; de la Serna E; Puig O; Castro-Fornieles J; Dolz M; Tor J; Parrilla S; Via E; Stephan-Otto C; Baeza I; Sugranyes G
    J Am Acad Child Adolesc Psychiatry; 2023 May; 62(5):593-600. PubMed ID: 36638884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study.
    Seidman LJ; Shapiro DI; Stone WS; Woodberry KA; Ronzio A; Cornblatt BA; Addington J; Bearden CE; Cadenhead KS; Cannon TD; Mathalon DH; McGlashan TH; Perkins DO; Tsuang MT; Walker EF; Woods SW
    JAMA Psychiatry; 2016 Dec; 73(12):1239-1248. PubMed ID: 27806157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probability of Transition to Psychosis in Individuals at Clinical High Risk: An Updated Meta-analysis.
    Salazar de Pablo G; Radua J; Pereira J; Bonoldi I; Arienti V; Besana F; Soardo L; Cabras A; Fortea L; Catalan A; Vaquerizo-Serrano J; Coronelli F; Kaur S; Da Silva J; Shin JI; Solmi M; Brondino N; Politi P; McGuire P; Fusar-Poli P
    JAMA Psychiatry; 2021 Sep; 78(9):970-978. PubMed ID: 34259821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention.
    Catalan A; Salazar de Pablo G; Vaquerizo Serrano J; Mosillo P; Baldwin H; Fernández-Rivas A; Moreno C; Arango C; Correll CU; Bonoldi I; Fusar-Poli P
    J Child Psychol Psychiatry; 2021 May; 62(5):657-673. PubMed ID: 32924144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year follow-up of a Chinese sample at clinical high risk for psychosis: timeline of symptoms, help-seeking and conversion.
    Zhang TH; Li HJ; Woodberry KA; Xu LH; Tang YY; Guo Q; Cui HR; Liu XH; Chow A; Li CB; Jiang KD; Xiao ZP; Seidman LJ; Wang JJ
    Epidemiol Psychiatr Sci; 2017 Jun; 26(3):287-298. PubMed ID: 27056022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.